Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Silverberg JI, et al. Among authors: romero w. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797-1810. doi: 10.1111/jdv.17351. Epub 2021 Jun 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33991374 Free PMC article. Review.
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Simpson EL, et al. Among authors: romero w. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Am J Clin Dermatol. 2021. PMID: 34406619 Free PMC article. Clinical Trial.
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Simpson EL, et al. Among authors: romero w. Am J Clin Dermatol. 2021 Nov;22(6):905. doi: 10.1007/s40257-021-00638-z. Am J Clin Dermatol. 2021. PMID: 34642878 Free PMC article. No abstract available.
High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Ständer S, Bhatia N, Gooderham MJ, Silverberg JI, Thyssen JP, Biswas P, DiBonaventura M, Romero W, Farooqui SA. Ständer S, et al. Among authors: romero w. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1308-1317. doi: 10.1111/jdv.18170. Epub 2022 May 6. J Eur Acad Dermatol Venereol. 2022. PMID: 35462428 Free PMC article.
Care pathways in atopic dermatitis: a retrospective population-based cohort study.
von Kobyletzki L, Ballardini N, Henrohn D, Neary MP, Ortsäter G, Geale K, Rieem Dun A, Lindberg I, De Geer A, Neregård P, Cha A, Cappelleri JC, Romero W, Thyssen JP. von Kobyletzki L, et al. Among authors: romero w. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1456-1466. doi: 10.1111/jdv.18185. Epub 2022 May 18. J Eur Acad Dermatol Venereol. 2022. PMID: 35470924 Free PMC article.
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Simpson EL, Silverberg JI, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Fan H, Farooqui SA, Chan G, Alderfer J, Romero W, Chittuluru K. Simpson EL, et al. Among authors: romero w. Am J Clin Dermatol. 2024 Jul;25(4):639-654. doi: 10.1007/s40257-024-00869-w. Epub 2024 Jun 18. Am J Clin Dermatol. 2024. PMID: 38888681 Free PMC article. Clinical Trial.
53 results